Showing results (131-140 of 347) with videos related to
Sort By:
Pageof 35
International Journal of Nephrology and Renovascular Disease|January 11, 2018
Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial resultsLarry A Weinrauch, Jiankang Liu, Brian Claggett, et al.Journal of Clinical Hypertension (Greenwich, Conn.)|October 21, 2014
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitusMatthew R Weir, Andrzej Januszewicz, Richard E Gilbert, et al.Journal of the American College of Emergency Physicians Open|October 11, 2021
Hyperkalemia management in the emergency department: An expert panel consensusZubaid Rafique, Frank Peacock, Terra Armstead, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 9, 2008
Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patientsBrian D Bradbury, Cathy W Critchlow, Matthew R Weir, et al.Journal of the National Medical Association|February 28, 2009
Predictors of compliance with antihypertensive therapy in a high-risk medicaid populationFadia T Shaya, Dongyi Du, Confidence M Gbarayor, et al.Current Medical Research and Opinion|June 8, 2017
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidenceMatthew R Weir, Jeffrey S Berger, Veronica Ashton, et al.Hypertension (Dallas, Tex. : 1979)|August 24, 2005
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensivesMatthew R Weir, Keith C Ferdinand, John M Flack, et al.American Heart Journal|March 1, 2020
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney diseaseMatthew R Weir, Veronica Ashton, Kenneth T Moore, et al.Clinical Kidney Journal|July 5, 2021
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) ProgramMatthew R Weir, April Slee, Tao Sun, et al.Medical Care|January 6, 2011
Readmissions after unauthorized discharges in the cardiovascular settingEberechukwu Onukwugha, C Daniel Mullins, F Ellen Loh, et al.Pageof 35